Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

157 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Oncolytic adenovirus and gene therapy with EphA2-BiTE for the treatment of pediatric high-grade gliomas.
Arnone CM, Polito VA, Mastronuzzi A, Carai A, Diomedi FC, Antonucci L, Petrilli LL, Vinci M, Ferrari F, Salviato E, Scarsella M, De Stefanis C, Weber G, Quintarelli C, De Angelis B, Brenner MK, Gottschalk S, Hoyos V, Locatelli F, Caruana I, Del Bufalo F. Arnone CM, et al. Among authors: de angelis b, de stefanis c. J Immunother Cancer. 2021 May;9(5):e001930. doi: 10.1136/jitc-2020-001930. J Immunother Cancer. 2021. PMID: 33963009 Free PMC article.
High-avidity cytotoxic T lymphocytes specific for a new PRAME-derived peptide can target leukemic and leukemic-precursor cells.
Quintarelli C, Dotti G, Hasan ST, De Angelis B, Hoyos V, Errichiello S, Mims M, Luciano L, Shafer J, Leen AM, Heslop HE, Rooney CM, Pane F, Brenner MK, Savoldo B. Quintarelli C, et al. Among authors: de angelis b. Blood. 2011 Mar 24;117(12):3353-62. doi: 10.1182/blood-2010-08-300376. Epub 2011 Jan 28. Blood. 2011. PMID: 21278353 Free PMC article.
Interleukin 15 provides relief to CTLs from regulatory T cell-mediated inhibition: implications for adoptive T cell-based therapies for lymphoma.
Perna SK, De Angelis B, Pagliara D, Hasan ST, Zhang L, Mahendravada A, Heslop HE, Brenner MK, Rooney CM, Dotti G, Savoldo B. Perna SK, et al. Among authors: de angelis b. Clin Cancer Res. 2013 Jan 1;19(1):106-17. doi: 10.1158/1078-0432.CCR-12-2143. Epub 2012 Nov 13. Clin Cancer Res. 2013. PMID: 23149818 Free PMC article.
Overcoming Challenges in CAR T-cell Product CGMP Release.
Quintarelli C, Locatelli F, Caruana I, De Angelis B. Quintarelli C, et al. Among authors: de angelis b. Mol Ther. 2016 May;24(5):845-6. doi: 10.1038/mt.2016.72. Mol Ther. 2016. PMID: 27198849 Free PMC article. No abstract available.
Bevacizumab-mediated tumor vasculature remodelling improves tumor infiltration and antitumor efficacy of GD2-CAR T cells in a human neuroblastoma preclinical model.
Bocca P, Di Carlo E, Caruana I, Emionite L, Cilli M, De Angelis B, Quintarelli C, Pezzolo A, Raffaghello L, Morandi F, Locatelli F, Pistoia V, Prigione I. Bocca P, et al. Among authors: de angelis b. Oncoimmunology. 2017 Oct 4;7(1):e1378843. doi: 10.1080/2162402X.2017.1378843. eCollection 2017. Oncoimmunology. 2017. PMID: 29296542 Free PMC article.
Adoptive Immunotherapy Using PRAME-Specific T Cells in Medulloblastoma.
Orlando D, Miele E, De Angelis B, Guercio M, Boffa I, Sinibaldi M, Po A, Caruana I, Abballe L, Carai A, Caruso S, Camera A, Moseley A, Hagedoorn RS, Heemskerk MHM, Giangaspero F, Mastronuzzi A, Ferretti E, Locatelli F, Quintarelli C. Orlando D, et al. Among authors: de angelis b. Cancer Res. 2018 Jun 15;78(12):3337-3349. doi: 10.1158/0008-5472.CAN-17-3140. Epub 2018 Apr 3. Cancer Res. 2018. PMID: 29615432
157 results